The emerging psychotropics industry will pave the way to a brighter future in mental health and overall wellness.
We believe in Enabling
Market Success.
We believe in Maintaining
Agility.
We believe in Growth Through
Innovation.
We believe in Our Ethical
Commitments.
We are a licensed manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies.
We are dedicated to the production of a variety of high-quality natural, synthetic, and biosynthetic products to meet the needs of the rapidly growing psychotropics-based medicines market.
Driven by a shared passion for mind science, our team is composed of leading experts from pharmaceutical development, biotechnology, agriculture, applied chemistry, and consumer product manufacturing industries.
A pioneer of emerging psychotropic drug markets and co-founder of one of the world’s best selling cannabis products, O.penVAPE, Mr. McElvany leverages more than a decade of experience pushing the boundaries of regulated drug market innovation and successful business operation.
His strategic market positioning and the development and broad licensing of key enabling technologies drove his company, Organa Brands, to an eventual $200 million (USD) acquisition by Slang Worldwide (SLGWF).
With a doctorate in pharmaceutical sciences, graduate studies in biochemistry, and a post-doctorate degree in pharmacology, Dr. Kazeminy has over 30 years of research and development experience in the biopharmaceutical industry, earning his place as a highly established authority of emerging biopharmaceutical advancement throughout the U.S. and Canada.
Having founded and served as CEO of Irvine Pharmaceutical Services Inc. and Avrio Biopharmaceutical LLC, Dr. Kazminy has served in a variety of positions over his impressive career, to include membership in the US Pharmacopeia Console of Experts and the UC Irvine Chief Executive Roundtable, to name a few.
Dr. Kazeminy is an expert in the facilitation of qualified trials and brings with him an undeniable track record of implementing best practices to ensure the validity and credibility of research outcomes. Dr. Kazeminy intends to leverage his vast network to enable the Lucy team to best support the psychotropic therapies industry as it continues to mature.
Highly experienced senior executive and former Executive Vice President and CFO at the Walt Disney Company, Mr. Nanula brings to bear a magnitude of leadership and strategy insights at the highest levels. Nanula’s various other executive roles include CEO of Broadband Sports, President and COO of Starwood Hotels, EVP of Finance and Strategy at Amgen, and Principal at Colony Capital.
In addition to Mr. Nanula’s executive leadership experience, he has also served in numerous director and advisory board positions throughout his professional tenure. Nanula is highly regarded as an investment advisor and is an esteemed graduate of Harvard Business School.
A leading corporate securities lawyer based in Calgary, Alberta, Canada for more than 25 years, Mr. Reeves leverages a wealth of experience in private and public debt and equity offerings, corporate acquisitions, structuring, and debt financing.
In addition to serving as Partner at TingleMerrett LLP since 2003, Reeves also acts as director of Radiko Holdings, Inc. (2017), Tree of Knowledge International Corp. (2018), Navion Capital Corp. (2018), CBD Global Sciences Inc. (2019), and Starrex International Ltd. (2019).
A globally renowned expert in data protection and privacy, technology policy, and legislative reform, Ms. Kaiser has worked on the leading edge of human-technology interface and education. Utilizing this foundational core of expertise, she has worked with various interdisciplinary teams to design, develop, and refine new technologies and consumer products.
Kaiser is the Co-Founder, President, and Director of the Own Your Data Foundation, and Co-Founder of the Digital Asset Trade Association (DATA) Technology for legal advocacy where she does legislative drafting and lobbying on privacy and blockchain initiatives.
With more than 40 years of experience in early-stage start-up, exploration financing, corporate governance, regulatory affairs, and project management, Mr. Susin represents a litany of strategy knowledge.
Susin is the Founder of Navion Capital Inc., a CPC listed on the TSX where he currently serves on the board of directors. Additionally, he has served on the boards of numerous publicly traded companies including Tock Tech Lithium Inc. and RDS Software, Inc.
As the chair of the Department of Psychiatry and Behavioral Sciences at the University of Texas, Austin, Dell Medical School, Dr. Nemeroff is a highly respected and well-published authority on international mental health research.
Dr. Nemeroff has received multiple awards for research and education in his field and has published more than 1,100 research reports and reviews. Additionally, Nemeroff has served in numerous esteemed board and council positions, including president of the American College of Psychiatrists and the American College of Neuropsychopharmacology.
A leader in corporate finance and strategy development, Mr. Abramowitz has led numerous successful ventures and high-value exits in his 35+ years of business experience. He has successfully helmed more than 20 enterprises driving change through strategic repositioning and organizational transformation.
Mr. Abramowitz founded a baby supply manufacturing company, Pur, leading it to numerous successes until it was acquired by Hasbro, Inc. Additionally, Abramowitz has served in various C-suite capacities, driving continuity and growth for Neah Power Systems, DAK Industries, Inn Keepers of America, and Experience Music Project.